[Immunosuppression - tough ally in torrid time]
- PMID: 26671921
- DOI: 10.5604/17322693.1184554
[Immunosuppression - tough ally in torrid time]
Abstract
Immunosuppression is a condition characterized by weakened or inhibited immune response. It occurred both in humoral and cellular response. This is related to the variable levels of deficiency for each antibody class (IgG, IgM, IgA) and a decrease in the number and function of immune cells, mainly T cells which results in the inhibition of cytokine production, signaling transduction and clonal expansion. Immunosuppressive therapy is used in many fields of medicine, such as transplantology, oncology, autoimmune disorders. Immunosuppression can be induced in several ways, by the surgical resection of the organs of the immune system, physical methods using X-rays or chemical methods using pharmacological agents. The most common way to induce immunosuppression is the administration of immunosuppressive drugs, amongst others: glucocorticoids, cytostatic drugs, immunophilin-binding agents, monoclonal antibodies. Unfortunately, the desired therapeutic effects of immunosuppression may be accompanied by a number of side effects associated with both impaired immunity (susceptibility to infections, including those caused by opportunistic microorganisms), toxic effects on the tissues (nephrotoxicity, neurotoxicity), or with a direct impact on the processes of malignancy. This harmful influence can be limited by the modification of the existing drugs, looking for new ones or developing new methods for the controlled kinetics of releasing the immunosuppressive pharmaceuticals. The personalization of immunosuppressant treatment according to genetic/genomic characteristics of individual patient represents the quite innovative look into the issue of immunosuppression.
Similar articles
-
Therapeutic uses of immune suppression and enhancement.Hosp Pract (Off Ed). 1981 Aug;16(8):93-101. doi: 10.1080/21548331.1981.11946818. Hosp Pract (Off Ed). 1981. PMID: 6266942 No abstract available.
-
Immunologic Monitoring to Personalize Immunosuppression After Liver Transplant.Gastroenterol Clin North Am. 2018 Jun;47(2):281-296. doi: 10.1016/j.gtc.2018.01.003. Gastroenterol Clin North Am. 2018. PMID: 29735024 Review.
-
[Immunosuppression in kidney transplantation].Ann Urol (Paris). 2007 Dec;41(6):276-84. doi: 10.1016/j.anuro.2007.08.006. Ann Urol (Paris). 2007. PMID: 18457319 Review. French.
-
[Immunosuppressive therapy in auto-immune diseases i. general fundamentals (author's transl)].Dermatol Monatsschr. 1978 Nov;164(11):769-78. Dermatol Monatsschr. 1978. PMID: 363471 Review. German. No abstract available.
-
Drug immunosuppression therapy for adult heart transplantation. Part 2: clinical applications and results.Ann Thorac Surg. 2004 Jan;77(1):363-71. doi: 10.1016/j.athoracsur.2003.07.007. Ann Thorac Surg. 2004. PMID: 14726105 Review.
Cited by
-
Influence of TGFB1 and CTLA4 polymorphisms on calcineurin inhibitors dose and risk of acute rejection in renal transplantation.Sci Rep. 2021 Sep 2;11(1):17531. doi: 10.1038/s41598-021-96457-7. Sci Rep. 2021. PMID: 34475433 Free PMC article.
-
Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.Pharmaceuticals (Basel). 2024 Jul 26;17(8):987. doi: 10.3390/ph17080987. Pharmaceuticals (Basel). 2024. PMID: 39204092 Free PMC article. Review.
-
The Effect of Chronic Immunosuppressive Regimens Treatment on Aortal Media Morphology and the Balance between Matrix Metalloproteinases (mmp-2 and mmp-9) and Their Inhibitors in the Abdominal Aorta of Rats.Int J Environ Res Public Health. 2022 May 24;19(11):6399. doi: 10.3390/ijerph19116399. Int J Environ Res Public Health. 2022. PMID: 35681984 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous